Decitabine

製品コードS1200 別名:Deoxycytidine

カスタマーフィードバック(3)

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

製品安全説明書

DNA Methyltransferase阻害剤の選択性比較

生物活性

製品説明 Decitabineは一種のDNA methylationの有効な阻害剤で、骨髄異形成症候群(MDS)を治療することに使用されます。
靶点
DNA methylation [1]
(HL-60, KG1a cells)
In vitro試験

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 Ml;ESpVv[3Srb36gRZN{[Xl? MUmwMlXDqM7:TR?= MnG4NlQhcA>? NFroRVl4[XSnch?= NG[wb3lud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>? MV2yOVEzOzB6Mh?=
Eca109 NH75XGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnJepo3OC53L{KuOU82KM7:TR?= M1LxXlI1NzR6L{eyJIg> MUf3ZZRmeg>? NYTuSZA5cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MoX3NlUyOjNyOEK=
Eca109 M3Hq[mZ2dmO2aX;uJGF{e2G7 NVq2UZpXOC53wrFOwG0> M2DKRVYwOTJxMkSgbC=> MYD3ZZRmeg>? NHK4UYpqdmirYnn0d{Bk\WyuIH3p[5JifGmxbtMg M{nz[lI2OTJ|MEiy
Eca109 MnLmSpVv[3Srb36gRZN{[Xl? NHLkWmUxNjYEoN88US=> M13KWVI1KGh? NIHSWZV4[XSnch?= M{K3Z4lvcGmkaYTzJINmdGxiaX72ZZNqd25? NWXBSpBROjVzMkOwPFI>
Eca109 NIXlTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mni3NE42yqEQvF2= MkPzNlQhcA>? NIfQ[VR4[XSnch?= NETOSllqdmS3Y3XzJGczN01iYYLy[ZN1KGmwIITo[UBk\WyuIHP5Z4xm M{DrblI2OTJ|MEiy
Eca109 NFr4NI1HfW6ldHnvckBCe3OjeR?= MYKwMlUwOSEQvF2= M2jwUFI1KGh? NFrodmV4[XSnch?= NYLsO4Jv\GWlcnXhd4V{KGW6cILld5Nqd25ib3[gUmYu|rqEMjDhcoQhVU2SMh?= NFXTXmgzPTF{M{C4Ni=>
SW1116  NFPrUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLifYtvOC53L{GvNk82KM7:TR?= M2C5fFQ5KGh? MXHEUXNQ M1L0c4VvcGGwY3XzJJRp\SCJZX\peIlvcWJiaX7keYNm\CClZXzsJIlvcGmkaYTpc44> NVL0eIx3OjR6N{SyPFY>
LOVO M1m1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\sT|AvPS9zL{KvOUDPxE1? MoPOOFghcA>? NIjhNWRFVVOR NYDaT5dW\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? NEH5U2kzPDh5NEK4Oi=>
SW1116  NGKwb4VHfW6ldHnvckBCe3OjeR?= NFv1b|IyOCEQvF2= M{SxZVQ5KGh? NHTZXHJFVVOR MYrpcoNz\WG|ZYOgeIhmKGWoZnXjeIl3\SCjdDDpcohq[mm2aX7nJGFMXCCjbnSgcXRQWiC|aXfuZYxqdmdicHH0bJdigXNiY3;tZolv\WRid3n0bEBo\W[rdHnubYI> MkTiNlQ5PzR{OE[=
LOVO NITzU49HfW6ldHnvckBCe3OjeR?= M1nBPVExKM7:TR?= M2XXd|Q5KGh? MmXPSG1UVw>? NFvEW|BqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? MmC3NlQ5PzR{OE[=
SW1116  MljxRZBweHSxc3nzJGF{e2G7 Ml7LNVAh|ryP M4XlXlQ5KGh? NXX2TY5KTE2VTx?= MW\lcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= MV[yOFg4PDJ6Nh?=
LOVO M1vKW2Fxd3C2b4Ppd{BCe3OjeR?= Ml;SNVAh|ryP MoTROFghcA>? Mom3SG1UVw>? Mn;J[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz MlzuNlQ5PzR{OE[=
RPMI-8226 NY\WbZZlSXCxcITvd4l{KEG|c3H5 Mn\FNU8zKM7:TR?= NGCzPWw1QC95Mj:5OkBp MkPtSG1UVw>? NX3MXoNucW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M1ruOFI1QDN|MUC4
OPM-2  M2TtVWFxd3C2b4Ppd{BCe3OjeR?= NVLoVIt7OS9{IN88US=> NF\3RXU4Oi97Nj:xNlAhcA>? MYDEUXNQ MnnVbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MViyOFg{OzFyOB?=
JJN3  NVT5XFBiSXCxcITvd4l{KEG|c3H5 M2Hke|AvPS9zIN88US=> NYHaS4lxOjRxNEigbC=> M3rvRWROW09? NH\MWY1qdmS3Y3XzJINmdGxiYYDvdJRwe2m| NWL3XoY{OjR6M{OxNFg>
NCI-H929  MWDBdI9xfG:|aYOgRZN{[Xl? M13OfFEwOiEQvF2= NFXRXFg4Oi97Nj:xNlAhcA>? M4fDN2ROW09? MXHpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M4TUZlI1QDN|MUC4
RPMI-8226 Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3O0UFEwOiEQvF2= MYmyOE81QC95MjDo NGH0[mFFVVOR MWrh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? MVyyOFg{OzFyOB?=
OPM-2  M2Ph[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXmNU8zKM7:TR?= NEj5NGEzPC92OD:3NkBp NU\sRoxzTE2VTx?= MmfUZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? NIiyS5AzPDh|M{GwPC=>
JJN3  M4T4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLnNE42NzFizszN MY[yOE81QC95MjDo NV;mT4JkTE2VTx?= MoLuZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? M2HsclI1QDN|MUC4
NCI-H929  M{HpUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOxM|Ih|ryP Mk\xNlQwPDhxN{KgbC=> NHfIcYtFVVOR MYrh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? MVuyOFg{OzFyOB?=
HeLa MmrhT4lv[XOnIFHzd4F6 MWHLbV0yODBy4pETOVAxOCEQvF2g[o9zKGiHTmSx NFnUTmEzPDd6MEC5PC=>
HeLa M1TocGtqdmG|ZTDBd5NigQ>? NXj5[pZrU2l;NT62JOKyKDBwNTFOwG0h\m:{IHjFUnQz M1nJSFI1PzhyMEm4
HeLa NV7CR5NqU2mwYYPlJGF{e2G7 MlSyT4k:OjFwNjFCtUA{NjBizszNJIZweiCqQ17UNS=> MYWyOFc5ODB7OB?=
HeLa M1G0N2tqdmG|ZTDBd5NigQ>? NULFXFZHU2l;MUSuOEDDuSB2Lk[g{txOKG[xcjDoR25VOw>? M3HMXlI1PzhyMEm4
NB4 MUHGeY5kfGmxbjDBd5NigQ>? NFL3XGwzNjVxNT:3MlUwOTBizszN NH3MPY4zPCCq NHj6cohFVVOR MX3pcoNz\WG|ZXGgeIhmKGW6cILld5Nqd25ib3[gdJJm[3W{c3;yJI1qWi1zMkXh MoHaNlQ1QDR6N{C=
CD4+ CD25− T  MUfGeY5kfGmxbjDBd5NigQ>? M2juRVEwPSEQvF2= M1fpbpJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>? MoDPNlQ1PzZ|NkC=
BV-173 M4fvWmFxd3C2b4Ppd{BCe3OjeR?= NUPyR4xUOC5{NT:wMlUwOC55NT:xJO69VQ>? MW[0PE84Oi97NjDo NGi3e4PDqFCEUx?= MX7pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= M1izZlI1PDJ|NkGz
ML-1 MX3BdI9xfG:|aYOgRZN{[Xl? MX:wMlI2NzBwNT:wMlc2NzFizszN NWO2PXd6PDhxN{KvPVYhcA>? M2fGeOKhWEKV NUPoUohxcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz MoL6NlQ1OjN4MUO=
HL-60 NG\INndCeG:ydH;zbZMhSXO|YYm= M4PJSlAvOjVxMD61M|AvPzVxMTFOwG0> NGDoSJA1QC95Mj:5OkBp MlroxsBRSlN? MVvpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NXfNV5Z5OjR2MkO2NVM>
KG-1a NFnMWFFCeG:ydH;zbZMhSXO|YYm= MofpNE4zPS9yLkWvNE44PS9zIN88US=> M1;QclQ5Nzd{L{m2JIg> MVdCpHBDWw>? NYXsbo02cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz MX2yOFQzOzZzMx?=
BV-173 M3y3U2Z2dmO2aX;uJGF{e2G7 MVuyOVAwPTBybl2= NXrIfGhoPDhiaB?= NEfV[|LDqFCEUx?= MnfabY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MnzxNlQ1OjN4MUO=
CEM NX;wfHdITnWwY4Tpc44hSXO|YYm= NIOwRXYzPTBxNUCwcm0> MkOzOFghcA>? NXPMTYVNyqCSQmO= M2O0V4lv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NVSyPHZPOjR2MkO2NVM>
HL-60 MUTGeY5kfGmxbjDBd5NigQ>? MYOyOVAwPTBybl2= MXO0PEBp M4Dn[uKhWEKV NXzkPItPcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl MmTqNlQ1OjN4MUO=
ML-1 NIC4UldHfW6ldHnvckBCe3OjeR?= MXuyOVAwPTBybl2= MlS2OFghcA>? NVThOFlpyqCSQmO= NXHSOVNbcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl M2LmVVI1PDJ|NkGz
DLD-1 MV3GeY5kfGmxbjDBd5NigQ>? NFHWdmkzPTBxNUCwcm0> NYTHXWhsPDhiaB?= M1vHO:KhWEKV MUTkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm M3XMVVI1PDJ|NkGz
HCT-116 MYjGeY5kfGmxbjDBd5NigQ>? MYKyOVAwPTBybl2= M1\BSVQ5KGh? NIi1UWPDqFCEUx?= NV7ZT2xz\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MlPjNlQ1OjN4MUO=
U937-A/E-9/14/18  MkHURZBweHSxc3nzJGF{e2G7 NEX4TpoxNjBzL{CuNU8yNzFyIN88US=> MXG0PEBp M1zjOIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NEXxPVkzPDNyMES1Oi=>
HT29 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnJO|IhcA>? NYPufmZrUUN3ME2xOFAxyrFzN{mg{txO MkPhNlQyPzJyNkG=
SW48 NVvsRm1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlznO|IhcA>? M2f0UWlEPTB;MUWuNuKyPi5{IN88US=> NVLjbXBPOjRzN{KwOlE>
HCT116 M{W2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYO3NkBp NFXwb3hKSzVyPUGuO:KyOC52IN88US=> NI\jSHczPDF5MkC2NS=>
HepG2 M3;tfGZ2dmO2aX;uJGF{e2G7 NF\vfXoxNjVxMTFOwG0> NF7BVWEzPCCq NFHlPXlFVVOR NWLtWW5GfXBvcnXneYxifGWmIITo[UBz\WyjdHn2[UBQS1SQMjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= M3joV|I1OTR4OEe0
LS174T Ml;1SpVv[3Srb36gRZN{[Xl? NWHsTJpUOC53L{Gg{txO MlTONlQhcA>? MmTxSG1UVw>? MUPs[YFlKHSxIHHuJIlv[3KnYYPlJI9nKE:FVF6yJIxmfmWucx?= NYnseJVWOjRzNE[4O|Q>
HepG2 MlHVRZBweHSxc3nzJGF{e2G7 MXmxM|ExNzFyMDFOwG0> NX;sclk5PyCm MkDHSG1UVw>? NV[4PWZ6cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NUXCWHR4OjRzNE[4O|Q>
LS174T Mm\nRZBweHSxc3nzJGF{e2G7 M2XLWlEwOTBxMUCwJO69VQ>? Mn;OO{Bl NFjOXJdFVVOR NXjhWGZvcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NEGxPHkzPDF2Nki3OC=>
QBC-939 Mn\FRZBweHSxc3nzJGF{e2G7 NXPtdXo4OS9zMD:xNFAh|ryP NH3ibWs4KGR? MoXISG1UVw>? MXzpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHW0TFIzPDF2Nki3OC=>
U251 NEjodnhCeG:ydH;zbZMhSXO|YYm= MnLJNU8yOC9zMECg{txO MV23JIQ> MXvEUXNQ NF7SbVlqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MX:yOFE1Pjh5NB?=
HL-60 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[xJO69VQ>? MVq0PEBp NGfBc2VqdmO{ZXHz[ZMhTzJvcHjhd4Uh[2WubDDmdoFkfGmxbh?= MUGyOFAxODN{NB?=
MDA‑MB‑453 MXrGeY5kfGmxbjDBd5NigQ>? NFf2UJoxNjJxMTFOwG0> M1vy[FczKGh? MnK3Z4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg M4DkNlI{QDR2MkK4
HCC1569 M1P2RWZ2dmO2aX;uJGF{e2G7 NXztOVNOOC5{L{Gg{txO NVPDVY96PzJiaB?= NEL2SHBk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> MUmyN|g1PDJ{OB?=
BT‑474 NWrteJRQTnWwY4Tpc44hSXO|YYm= M13qXVAvOi9zIN88US=> M2O1blczKGh? NV3LZmhK[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh NHjpPYIzOzh2NEKyPC=>
AGS MmfkRZBweHSxc3nzJGF{e2G7 M4HYT|UwOTBxMkCvOVAh|ryP NV7iWHpSPDkEoHlCpC=> M3zLdGROW09? M2XJdolvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh M17ydlI{PTh{N{i0
A549 NVzsfVF[SXCxcITvd4l{KEG|c3H5 MXm1M|ExNzJyL{WwJO69VQ>? MnfzOFjDqGkEoB?= NFfQXXNFVVOR NU\5S2JHcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB? MlzMNlM2QDJ5OES=
AGS  MnPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;FSlUwOTBxMkCvOVAh|ryP Mo\ZOFjDqGkEoB?= NIDY[4JFVVOR MXPpcoR2[2W|IFeyM20heGijc3WgZZJz\XO2wrC= NHLXT|AzOzV6Mke4OC=>
Kasumi-1 NE\jbmxCeG:ydH;zbZMhSXO|YYm= NEW0Wm4xNjVizszN NH3HTFg1QMLiaNMg M4TzbIRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj MXWyN|Q6OzN2OB?=
OCI-AML3 MWjBdI9xfG:|aYOgRZN{[Xl? MXiyMlUh|ryP Mlm3OFjDqGkEoB?= MWjk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= NWfnTIpqOjN2OUOzOFg>
MV4-11 NHXndVdCeG:ydH;zbZMhSXO|YYm= M2XXcFIvPSEQvF2= Ml\JOFjDqGkEoB?= MUXk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= M4TkcFI{PDl|M{S4
NK  MVrDfZRwfG:6aYT5JGF{e2G7 NWD0d3F1OC5yMj2yNEDPxE1? MlvsOUBl M4m1VYRm[3KnYYPld{B1cGViY4n0c4x6fGmlIHHjeIl3cXS7IH;mJG5MKGOnbHzzJIF1KGmwdHXycYVlcWG2ZTDjc45k\W62cnH0bY9veyC{ZYP1cJRqdmdiaX6gZUBWNXOqYYDl[EBld3On4pETdoV{eG:wc3WgZ5VzfmV? MXiyN|MzQDB6OB?=
NK  M4S4dWFxd3C2b4Ppd{BCe3OjeR?= NHPGeXgxNjB{LUKwJO69VQ>? Mn7FOUBl MlWz[IVkemWjc3WgUmsh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdImgZZMhfGinIHPvcoNmdnS{YYTpc44hcW6lcnXhd4Vl MV2yN|MzQDB6OB?=
NK  NUi0bZpxTnWwY4Tpc44hSXO|YYm= M322Z|AvODFvMkCg{txO NHn3TZo2KGR? M{WwOINifXOnczDofZBwdWW2aInsZZRqd25ib3[gUmsh[2WubIOgbY4h[SCmb4Pl5qCUemW|cH;ud4U> M1vFU|I{OzJ6MEi4
MOLT4/DNR MXfGeY5kfGmxbjDBd5NigQ>? MVO1JO69VQ>? NUGxRZJlPCCm NXvTcGtsemWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? MU[yN|A3ODV5MB?=
Jurkat/DOX NHHn[2ZHfW6ldHnvckBCe3OjeR?= MnTSOUDPxE1? M2e3bFQh\A>? M3;lSpJm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v MW[yN|A3ODV5MB?=
MOLT4/DNR M4j1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HPSVUh|ryP NXPPNGNGPCCm M{XKT5Jm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= NFzacpAzOzB4MEW3NC=>
Jurkat/DOX MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYK1JO69VQ>? MUO0JIQ> MV;y[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 MWmyN|A3ODV5MB?=
ccRCC  MV7BdI9xfG:|aYOgRZN{[Xl? MmrUNE4xOS1zMN88US=> NIO2dGs4OiCq M3rNTmROW09? MYnoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v M2nsNVIzQDJ4NE[3
TNBC  NU\C[5RQSXCxcITvd4l{KEG|c3H5 M2fobVAvODFvMUFOwG0> NFvPVmo4OiCq Mnm0SG1UVw>? MX7oZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v MorsNlI5OjZ2Nke=
A498 MoPuRZBweHSxc3nzJGF{e2G7 NHz0bYExNjBzLUGw{txO NYXTRWEyPzJiaB?= NWrySW9ETE2VTx?= NVHob2RLcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? NVLsTXlOOjJ6Mk[0Olc>
KIJ265T NE\sOVlCeG:ydH;zbZMhSXO|YYm= NX3NW24xOC5yMT2xNO69VQ>? MWq3NkBp Mor3SG1UVw>? NVPwXnFucW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? NYP5Z3NEOjJ6Mk[0Olc>
MDA-231 MYfBdI9xfG:|aYOgRZN{[Xl? M2C4fFAvODFvMUFOwG0> NYr2dVNuPzJiaB?= MUHEUXNQ MXLpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu MkjTNlI5OjZ2Nke=
BT-20 NVnmS4hiSXCxcITvd4l{KEG|c3H5 MVuwMlAyNTFyzszN NYDuc|hiPzJiaB?= MWfEUXNQ NIHHZ4FqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NHjneHUzOjh{NkS2Oy=>
U937 MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnieYVEPS1{MDFOwG0> NUnjO5piOjRxNEivO|IhcA>? M3OzbYlv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NWDIN4FWOjJ5NkewNlE>
HL60 MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn6OU0zOCEQvF2= M1fsbVI1NzR6L{eyJIg> NW\0V4pHcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M4TkZ|IzPzZ5MEKx
U937 M1j1TmFxd3C2b4Ppd{BCe3OjeR?= NUG1NG54OTVizszN MmiwNlQwPDhxN{KgbC=> NInaO5FqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NGDUXFUzOjd4N{CyNS=>
HL60 NXLETpNXSXCxcITvd4l{KEG|c3H5 MVyxOUDPxE1? NX;Xe4g3OjRxNEivO|IhcA>? NWP6TVFVcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NFS5c|AzOjd4N{CyNS=>
LS411N  M2LYXGFxd3C2b4Ppd{BCe3OjeR?= NF:3[okxNjVizszN MkjYO|IhcA>? NHXuVYZqdmO{ZXHz[ZMhTmG|IH3SUmEhdGW4ZXy= NWO3UHNWOjJ2NkG2PVU>
MDA-MB-231 NFf2OYxCeG:ydH;zbZMhSXO|YYm= M2L1NVExKM7:TR?= M4GxfFQ5KGh? NIHkfZZz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MVuyNVg5PzZ7Nx?=
MCF-7  NWHne|F1SXCxcITvd4l{KEG|c3H5 M1TWOlExKM7:TR?= Mo\MOFghcA>? NHXQU5Nz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NVnuOGxmOjF6OEe2PVc>
A375 MkjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXjcllJOC53IN88US=> M2rpPVEwPS96IHS= M2rMZYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| Mn33NlE4QTZ4MkK=
SKMEL1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PRb|AvPSEQvF2= NXnCPIczOS93L{ig[C=> M{PYb4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MWiyNVc6PjZ{Mh?=
SKMEL3 NUO0PVF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPqNE42KM7:TR?= M1PZRVEwPS96IHS= M4\rNolvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| M2mxfFIyPzl4NkKy
SKMEL28 NWL2UFJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jrOlAvPSEQvF2= NEDLfpkyNzVxODDk M2\ibolvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NV;IXYIzOjF5OU[2NlI>
MeWo MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV6wMlUh|ryP NWHIXFJQOS93L{ig[C=> M3fGOYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NE\EXYczOTd7Nk[yNi=>
B16 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXmwMlUh|ryP M4rP[|EwPS96IHS= Ml\kbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MUSyNVc6PjZ{Mh?=
Ly 1 MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWeyOEBp NWO3enk6UUN3ME23MlMh|ryP Ml:5NlE4PzJyNEm=
Ly 7 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjpSnlyOjRiaB?= MkPHTWM2OD1zMD63JO69VQ>? NGPxdpAzOTd5MkC0PS=>
Su-DHL6 M3zyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mom3NlQhcA>? MVfJR|Ux97zgMkCg{txO M1PIO|IyPzd{MES5
Ly 10 Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXyS4EzPCCq Mo\2TWM2OO,:nkKwJO69VQ>? MmrnNlE4PzJyNEm=
RIVA MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jsZ|I1KGh? NIW0bmxKSzVy78{eNlAh|ryP Ml3VNlE4PzJyNEm=
Su-DHL2 Mlf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\0RVI1KGh? NWXYN5YyUUN3MP-8olIxKM7:TR?= MlXHNlE4PzJyNEm=
Ly 1 NF7ndZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\RTnE1QCCq MWrJR|UxRTBwM{Sg{txO NGPzXJYzOTd5MkC0PS=>
Ly 7 NEXGdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDCTnZRPDhiaB?= MnzCTWM2OD1yLkCyOUDPxE1? MYiyNVc4OjB2OR?=
Su-DHL6 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1X2clQ5KGh? MULJR|Ux97zgMkCg{txO MmLhNlE4PzJyNEm=
Ly 10 NWewe5BKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHUWok1QCCq M33DUWlEPTB;MT64JO69VQ>? NVm3e3ZOOjF5N{KwOFk>
RIVA MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnuVnk1QCCq MVHJR|Ux97zgMkCg{txO NX;5dJRHOjF5N{KwOFk>
Su-DHL2 MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzaOFghcA>? MoH2TWM2OD1zNz60JO69VQ>? NWnpR3ZLOjF5N{KwOFk>
Ly 1 NE\nPIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnFO|IhcA>? M{D4TmlEPTB;MD6wNUDPxE1? M1PYU|IyPzd{MES5
Ly 7 M{O5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXKVXdZPzJiaB?= MX;JR|UxRTBwMEG4JO69VQ>? NX3lfHQzOjF5N{KwOFk>
Su-DHL6 M2jaeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYS3NkBp NHraUJNKSzVyPUGuOkDPxE1? MY[yNVc4OjB2OR?=
Ly 10 NX\xenAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PYPVczKGh? NEfSfXdKSzVyPUGuNkDPxE1? MlS4NlE4PzJyNEm=
RIVA MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYK0OJdRPzJiaB?= M2nH[2lEPTExvK6yNEDPxE1? Mn:4NlE4PzJyNEm=
Su-DHL2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTTUFY4OiCq NF7FeXJKSzVyPUGxMlIh|ryP MYiyNVc4OjB2OR?=

... Click to View More Cell Line Experimental Data

In vivo試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

プロトコル(参考用のみ)

キナーゼアッセイ:[1]
+ 展開

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
細胞アッセイ: [1]
+ 展開
  • 細胞株: HL-60 and KG1a
  • 濃度: 0-500 nM
  • 反応時間: 96 hours
  • 実験の流れ: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (参考用のみ)
動物実験:[2]
+ 展開
  • 動物モデル: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • 製剤: Decitabine is dissolved in sterile PBS .
  • 投薬量: ≤2.5 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol <1 mg/mL
体内 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL

* <1 mg/mlは製品が微弱に溶解する或いは溶解しないことを示します。
* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
保管
in solvent
別名 Deoxycytidine

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT01479348 Enrolling by invitation Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 28, 2011 Early Phase 1
NCT03041688 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|TP53 wt Allele|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) October 2017 Phase 1
NCT03009240 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 1
NCT02890329 Not yet recruiting Chimerism|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2017 Phase 1
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center March 2017 Early Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

DNA Methyltransferase信号経路図

Tags: Decitabineを買う | Decitabine ic50 | Decitabine供給者 | Decitabineを購入する | Decitabine費用 | Decitabine生産者 | オーダーDecitabine | Decitabine化学構造 | Decitabine分子量 | Decitabine代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID